Showing 3521-3530 of 7035 results for "".
- Meet JAAD's New Editor Dirk M. Elston, MDhttps://practicaldermatology.com/news/meet-jaads-new-editor-dirk-m-elston-md/2457918/Charleston, SC-based dermatologist Dirk M. Elston, MD, FAAD, is the next editor of the Journal of the American Academy of Dermatology. Dr. Elston, the journal’s current deputy editor, will step into his new role in July 2018, succeeding de
- La Roche-Posay Nabs 20 Beauty Awards in 2016https://practicaldermatology.com/news/la-roche-posay-nabs-20-beauty-awards-in-2016/2458336/La Roche-Posay (LRP) won 20 beauty awards, almost doubling its wins from the previous year, the company has announced. The awards, judged by editors, industry leaders and elite experts who test thousands of beauty products before awarding top honors, bring the total skincare wins for LRP to 55 an
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://practicaldermatology.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://practicaldermatology.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.
- BE RADIANT: Bimekizumab Delivers Durable Plaque PsO Gains Through 3 Yearshttps://practicaldermatology.com/news/be-radiant-bimekizumab-delivers-durable-pro-gains-through-3-years/2485749/Bimekizumab treatment was associated with rapid and sustained improvements in patient-reported outcomes (PROs) among adults with moderate to seve
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://practicaldermatology.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://practicaldermatology.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://practicaldermatology.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a